Table 3: Cardiovascular effects of anti-diabetic drugs
Cardiovascular events represent the greatest complication of diabetes. Evidence suggests that metformin improves CV outcomes in patients with diabetes, especially in the United Kingdom Prospective Diabetes Study (UKPDS) and other subsequent studies, by different mechanisms. There are few cardiova...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Sello Editorial Lugones
2020-09-01
|
| Series: | Revista de la Sociedad Argentina de Diabetes |
| Subjects: | |
| Online Access: | https://revistasad.com/index.php/diabetes/article/view/253 |
| _version_ | 1797984042710204416 |
|---|---|
| author | Pablo Javier Avila Silvana Milrad Mariano Forlino Sofía Fabregues Fabiana Vázquez Cristina Grosso Ana Schindler Fabio Zambon María Virginia Rodríguez Natalia Carolina Garrido Santos Laura Calvo Alejandra Maldini Sandra Maserati Romina Stagno |
| author_facet | Pablo Javier Avila Silvana Milrad Mariano Forlino Sofía Fabregues Fabiana Vázquez Cristina Grosso Ana Schindler Fabio Zambon María Virginia Rodríguez Natalia Carolina Garrido Santos Laura Calvo Alejandra Maldini Sandra Maserati Romina Stagno |
| author_sort | Pablo Javier Avila |
| collection | DOAJ |
| description | Cardiovascular events represent the greatest complication of diabetes. Evidence suggests that metformin improves CV outcomes in patients with diabetes, especially in the United Kingdom Prospective Diabetes Study (UKPDS) and other subsequent studies, by different mechanisms.
There are few cardiovascular safety studies for sulfonylureas although they would not have a safe profile at this level. Gliclazide appears to be the best performing drug in this group. Something similar occurs with meglitinides for which the data indicates that they would not increase the risk but neither would they improve the incidence of cardiovascular events.
Thiazolidinediones are the most questioned drugs, although the studies and meta-analyzes are contradictory, there would be no doubt that they increase the risk of heart failure. DPPIV inhibitors showed neutral results except for saxagliptin, which would increase the risk of hospitalization for heart failure.
There is convincing data that SGLT-2 receptor inhibitors at the renal level and intestinal GLP-1 analogues have positive effects at the cardiovascular level with some differences between the members of these families.
Regarding insulins, studies suggest that both slow and fast analogues would have a better cardiovascular profile, mainly linked to the lower incidence of severe hypoglycemia, than NPH and regular insulin, respectively. |
| first_indexed | 2024-04-11T06:55:28Z |
| format | Article |
| id | doaj.art-33d382724bed44cca8b0ee5b5aa57750 |
| institution | Directory Open Access Journal |
| issn | 0325-5247 2346-9420 |
| language | Spanish |
| last_indexed | 2024-04-11T06:55:28Z |
| publishDate | 2020-09-01 |
| publisher | Sello Editorial Lugones |
| record_format | Article |
| series | Revista de la Sociedad Argentina de Diabetes |
| spelling | doaj.art-33d382724bed44cca8b0ee5b5aa577502022-12-22T04:39:02ZspaSello Editorial LugonesRevista de la Sociedad Argentina de Diabetes0325-52472346-94202020-09-01542Sup10712210.47196/diab.v54i2Sup.253197Table 3: Cardiovascular effects of anti-diabetic drugsPablo Javier Avila0Silvana Milrad1Mariano Forlino2Sofía Fabregues3Fabiana Vázquez4Cristina Grosso5Ana Schindler6Fabio Zambon7María Virginia Rodríguez8Natalia Carolina Garrido Santos9Laura Calvo10Alejandra Maldini11Sandra Maserati12Romina Stagno13Sociedad Argentina de Diabetes (SAD), Obra Social de Empleados Públicos, San Rafael, Mendoza, ArgentinaSociedad Argentina de Diabetes (SAD), Hospital de Rehabilitación Manuel Rocca, Gobierno de la Ciudad de Buenos Aires (GCBA), Ciudad Autónoma de Buenos Aires, ArgentinaSociedad Argentina de Diabetes (SAD), Centro Médico IMED, San Luis, Argentina.Sociedad Argentina de Diabetes (SAD), Centro de Salud y Acción Comunitario, Nivel 1, Balvanera (CeSAC Nº 11), Ciudad Autónoma de Buenos Aires, ArgentinaSociedad Argentina de Diabetes (SAD), Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires, ArgentinaSociedad Argentina de Diabetes (SAD), Hospital Municipal de Vicente López, Provincia de Buenos Aires, ArgentinaSociedad Argentina de Diabetes (SAD), Centro de Salud y Acción Comunitario Nivel 1 (CeSAC) N° 15, Ciudad Autónoma de Buenos Aires, ArgentinaSociedad Argentina de Diabetes (SAD), Ciudad Autónoma de Buenos Aires, ArgentinaSociedad Argentina de Diabetes (SAD), Ciudad Autónoma de Buenos Aires, ArgentinaSociedad Argentina de Diabetes (SAD), Ciudad Autónoma de Buenos Aires, ArgentinaSociedad Argentina de Diabetes (SAD), Hospital Independencia, Santiago del Estero, ArgentinaSociedad Argentina de Diabetes (SAD), Centro de Salud Santa Rosa, Universidad Nacional de La Pampa, La Pampa, ArgentinaSociedad Argentina de Diabetes (SAD), Centro de Diabetes de Pilar, Municipalidad de Pilar, Provincia de Buenos Aires, ArgentinaSociedad Argentina de Diabetes (SAD), Hospital Municipal de Colón y Hospital Municipal de Chacabuco, Provincia de Buenos Aires, ArgentinaCardiovascular events represent the greatest complication of diabetes. Evidence suggests that metformin improves CV outcomes in patients with diabetes, especially in the United Kingdom Prospective Diabetes Study (UKPDS) and other subsequent studies, by different mechanisms. There are few cardiovascular safety studies for sulfonylureas although they would not have a safe profile at this level. Gliclazide appears to be the best performing drug in this group. Something similar occurs with meglitinides for which the data indicates that they would not increase the risk but neither would they improve the incidence of cardiovascular events. Thiazolidinediones are the most questioned drugs, although the studies and meta-analyzes are contradictory, there would be no doubt that they increase the risk of heart failure. DPPIV inhibitors showed neutral results except for saxagliptin, which would increase the risk of hospitalization for heart failure. There is convincing data that SGLT-2 receptor inhibitors at the renal level and intestinal GLP-1 analogues have positive effects at the cardiovascular level with some differences between the members of these families. Regarding insulins, studies suggest that both slow and fast analogues would have a better cardiovascular profile, mainly linked to the lower incidence of severe hypoglycemia, than NPH and regular insulin, respectively.https://revistasad.com/index.php/diabetes/article/view/253agentes antidiabéticosdiabetes mellituseventos cardiovascularesestudios de seguridad cardiovascularantidiabéticos oralesinsulina |
| spellingShingle | Pablo Javier Avila Silvana Milrad Mariano Forlino Sofía Fabregues Fabiana Vázquez Cristina Grosso Ana Schindler Fabio Zambon María Virginia Rodríguez Natalia Carolina Garrido Santos Laura Calvo Alejandra Maldini Sandra Maserati Romina Stagno Table 3: Cardiovascular effects of anti-diabetic drugs Revista de la Sociedad Argentina de Diabetes agentes antidiabéticos diabetes mellitus eventos cardiovasculares estudios de seguridad cardiovascular antidiabéticos orales insulina |
| title | Table 3: Cardiovascular effects of anti-diabetic drugs |
| title_full | Table 3: Cardiovascular effects of anti-diabetic drugs |
| title_fullStr | Table 3: Cardiovascular effects of anti-diabetic drugs |
| title_full_unstemmed | Table 3: Cardiovascular effects of anti-diabetic drugs |
| title_short | Table 3: Cardiovascular effects of anti-diabetic drugs |
| title_sort | table 3 cardiovascular effects of anti diabetic drugs |
| topic | agentes antidiabéticos diabetes mellitus eventos cardiovasculares estudios de seguridad cardiovascular antidiabéticos orales insulina |
| url | https://revistasad.com/index.php/diabetes/article/view/253 |
| work_keys_str_mv | AT pablojavieravila table3cardiovasculareffectsofantidiabeticdrugs AT silvanamilrad table3cardiovasculareffectsofantidiabeticdrugs AT marianoforlino table3cardiovasculareffectsofantidiabeticdrugs AT sofiafabregues table3cardiovasculareffectsofantidiabeticdrugs AT fabianavazquez table3cardiovasculareffectsofantidiabeticdrugs AT cristinagrosso table3cardiovasculareffectsofantidiabeticdrugs AT anaschindler table3cardiovasculareffectsofantidiabeticdrugs AT fabiozambon table3cardiovasculareffectsofantidiabeticdrugs AT mariavirginiarodriguez table3cardiovasculareffectsofantidiabeticdrugs AT nataliacarolinagarridosantos table3cardiovasculareffectsofantidiabeticdrugs AT lauracalvo table3cardiovasculareffectsofantidiabeticdrugs AT alejandramaldini table3cardiovasculareffectsofantidiabeticdrugs AT sandramaserati table3cardiovasculareffectsofantidiabeticdrugs AT rominastagno table3cardiovasculareffectsofantidiabeticdrugs |